Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
Alzamend Neuro, Inc. (ALZN)
Company Research
Source: Business Wire
Fireside conversation to take place on October 17, 2024, at 1:30 PM ET ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that CEO Stephan Jackman will participate in a fireside chat at the upcoming Maxim Group Virtual Healthcare Conference. The conversation will take place with a senior member of Maxim Group’s biotech research team on Thursday, October 17, 2024, at 1:30 pm ET. Mr. Jackman looks forward to providing an overview of Alzamend’s therapeutic pipeline, followed by an interactive discussion and question-and-answer session. Anyone interested in watching can register here: https://m-vest.com/events/healthcare-10152024.Summary of the Maxim Group Virtual Healthcare ConferenceThe Maxim Group Virtual
Show less
Read more
Impact Snapshot
Event Time:
ALZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALZN alerts
High impacting Alzamend Neuro, Inc. news events
Weekly update
A roundup of the hottest topics
ALZN
News
- Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’sBusiness Wire
- EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's [Yahoo! Finance]Yahoo! Finance
- Alzamend Neuro regains compliance with Nasdaq [Seeking Alpha]Seeking Alpha
- Alzamend Neuro Regains Compliance with Nasdaq Listing StandardsBusiness Wire
- Alzamend Neuro Issues Letter to StockholdersBusiness Wire
ALZN
Sec Filings
- 10/15/24 - Form 8-K
- 10/3/24 - Form 424B5
- 10/3/24 - Form 8-K
- ALZN's page on the SEC website